Idorsia's insomnia treatment Quviviq was approved by the FDA last year and endorsed by actress Jennifer Aniston and Olympic skier Lindsey Vonn. Swiss firm with Radnor operations gets FDA approval ...

May 2, 2022 /PRNewswire/ -- Idorsia Ltd (SIX: IDIA) & Idorsia Pharmaceuticals, US Inc. today announced that QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are now commercially available for ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

collaborative development and commercialization agreement in respect to vamorolone between ReveraGen BioPharma Inc. and Idorsia in its entirety to Santhera Pharmaceuticals, whereby Santhera shall ...

Idorsia will now discuss the results with ... CHF 1M for Daridorexant from Mochida Pharmaceutical Co., Ltd. (TYO:4534), and CHF 1M Neurocrine Biosciences (NASDAQ:NBIX) for the development and ...

Based in Allschwil, Switzerland, Idorsia has its U.S. operations — Idorsia Pharmaceuticals USA — in Radnor, where the company employs about 125 workers. Idorsia, which has about 1,100 ...

For further information, please contact Investor & Media Relations Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 investor.relations@idorsia.com - media ...

Push to remove a newer class of insomnia drugs from the controlled substance list based on data demonstrating negligible potential for abuse Sponsored by Idorsia Pharmaceuticals David, a retired ...

EWING, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that its ...

Idorsia Pharmaceuticals plans for widespread availability in the US by the second half of 2024 to benefit the millions of patients who cannot control their hypertension with other drugs.

Ad hoc announcement pursuant to Art. 53 LR Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study Idorsia ...

Idorsia Pharmaceuticals, US Inc. today announced that QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are now commercially available for adult patients with insomnia, which is characterized ...